234 related articles for article (PubMed ID: 19853923)
1. Chlamydial protease-like activity factor--insights into immunity and vaccine development.
Murthy AK; Guentzel MN; Zhong G; Arulanandam BP
J Reprod Immunol; 2009 Dec; 83(1-2):179-84. PubMed ID: 19853923
[TBL] [Abstract][Full Text] [Related]
2. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.
Murthy AK; Cong Y; Murphey C; Guentzel MN; Forsthuber TG; Zhong G; Arulanandam BP
Infect Immun; 2006 Dec; 74(12):6722-9. PubMed ID: 17015458
[TBL] [Abstract][Full Text] [Related]
3. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
Agrawal T; Vats V; Salhan S; Mittal A
J Reprod Immunol; 2009 Dec; 83(1-2):173-8. PubMed ID: 19896206
[TBL] [Abstract][Full Text] [Related]
4. Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis.
Rey-Ladino J; Ross AG; Cripps AW
Hum Vaccin Immunother; 2014; 10(9):2664-73. PubMed ID: 25483666
[TBL] [Abstract][Full Text] [Related]
5. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.
Li W; Murthy AK; Lanka GK; Chetty SL; Yu JJ; Chambers JP; Zhong G; Forsthuber TG; Guentzel MN; Arulanandam BP
Vaccine; 2013 Nov; 31(48):5722-8. PubMed ID: 24096029
[TBL] [Abstract][Full Text] [Related]
6. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
[TBL] [Abstract][Full Text] [Related]
7. Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains.
Su H; Messer R; Whitmire W; Hughes S; Caldwell HD
Infect Immun; 2000 Jan; 68(1):192-6. PubMed ID: 10603387
[TBL] [Abstract][Full Text] [Related]
8. The role of an enzymatically inactive CPAF mutant vaccination in Chlamydia muridarum genital tract infection.
Chen H; Peng B; Yang C; Xie L; Zhong S; Sun Z; Li Z; Wang C; Liu X; Tang X; Zhong G; Lu C
Microb Pathog; 2021 Nov; 160():105137. PubMed ID: 34390765
[TBL] [Abstract][Full Text] [Related]
9. HtrA, RseP, and Tsp proteins do not elicit a pathology-related serum IgG response during sexually transmitted infection with Chlamydia trachomatis.
Huston WM; Armitage CW; Lawrence A; Gloeckl S; Bell SJ; Debattista J; Allan JA; Timms P;
J Reprod Immunol; 2010 Jun; 85(2):168-71. PubMed ID: 20444505
[TBL] [Abstract][Full Text] [Related]
10. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae.
Su H; Messer R; Whitmire W; Fischer E; Portis JC; Caldwell HD
J Exp Med; 1998 Sep; 188(5):809-18. PubMed ID: 9730883
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.
Farris CM; Morrison RP
Infect Immun; 2011 Mar; 79(3):986-96. PubMed ID: 21078844
[TBL] [Abstract][Full Text] [Related]
12. Towards a Chlamydia trachomatis vaccine: how close are we?
Cochrane M; Armitage CW; O'Meara CP; Beagley KW
Future Microbiol; 2010 Dec; 5(12):1833-56. PubMed ID: 21155665
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.
Li W; Murthy AK; Guentzel MN; Seshu J; Forsthuber TG; Zhong G; Arulanandam BP
J Immunol; 2008 Mar; 180(5):3375-82. PubMed ID: 18292563
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge.
Murthy AK; Li W; Guentzel MN; Zhong G; Arulanandam BP
Vaccine; 2011 Mar; 29(14):2519-22. PubMed ID: 21300093
[TBL] [Abstract][Full Text] [Related]
15. Action Needed on Chlamydia Vaccines.
Starnbach MN
Trends Microbiol; 2018 Aug; 26(8):639-640. PubMed ID: 29858127
[TBL] [Abstract][Full Text] [Related]
16. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of protective and immune responses following vaccination with recombinant MIP and CPAF from Chlamydia abortus as novel vaccines for enzootic abortion of ewes.
O'Neill LM; Keane OM; Ross PJ; Nally JE; Seshu J; Markey B
Vaccine; 2019 Aug; 37(36):5428-5438. PubMed ID: 31375438
[TBL] [Abstract][Full Text] [Related]
18. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.
Chaganty BK; Murthy AK; Evani SJ; Li W; Guentzel MN; Chambers JP; Zhong G; Arulanandam BP
Vaccine; 2010 Mar; 28(11):2323-9. PubMed ID: 20056182
[TBL] [Abstract][Full Text] [Related]
19. Chlamydia trachomatis infection: host immune responses and potential vaccines.
Hafner L; Beagley K; Timms P
Mucosal Immunol; 2008 Mar; 1(2):116-30. PubMed ID: 19079169
[TBL] [Abstract][Full Text] [Related]
20. Chlamydia trachomatis: Protective Adaptive Responses and Prospects for a Vaccine.
Poston TB; Darville T
Curr Top Microbiol Immunol; 2018; 412():217-237. PubMed ID: 27033698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
